FDA cracks down on clinics selling unapproved stem cell therapies – CBS News
CBS News |
FDA cracks down on clinics selling unapproved stem cell therapies
CBS News The U.S. Food and Drug Administration announced a crackdown on stem–cell clinics marketing and selling unapproved and potentially harmful therapies for cancer and other diseases. The agency took action against two large clinics in Florida and … FDA moves to curb dangerous stem cell clinicsPhilly.com FDA cracks down on clinics selling unproven stem cell ‘therapies’Los Angeles Times FDA raids stem cell lab, warns anotherThe Boston Globe New York Times –NPR –Marketplace.org –FDA.gov all 75 news articles » |
Wicked Local Ipswich |
Ipswich resident Talia Duff’s fight for life continues, family hopes to raise funds for research
Wicked Local Ipswich The gene therapy that could save Talia’s life could also have a wide-reaching effect on how rare disease are treated throughout the world. Potentially, others who suffer from a one-gene mutation defect could benefit by replicating the same sort of … |
The Nation. |
We’re Failing Our Test Run for the Age of CRISPR
The Nation. In MIT Technology Review, we learned that, for the first time in the United States, researchers had used the gene-editing technique known as CRISPR to modify a human embryo. Several days later, CBS News released a report that through nearly universal … |
Rare Disease Report |
Abeona Gene Therapy for Epidermolysis Bullosa Continues to Impress the FDA
Rare Disease Report “EB-101 is an autologous gene-corrected cell therapeutic approach that utilizes a patient’s own cells and genetically engineering them to produce the correct version of collagen, which helps hold skin on to the body, thereby reducing the number of … Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in …Nasdaq |
FiercePharma |
How will Gilead price CAR–T? With Kite buy, the top biotech joins Novartis in spotlight
FiercePharma Novartis will likely have to produce numbers first: It’s positioned to reach the market ahead of Kite with its CAR–T with its med, CTL019, to treat pediatric and young adult patients with B-cell ALL. The drug won an FDA panel’s unanimous backing in June. Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR TBioPharma-Reporter.com Gilead Looks To Become The White Knight Of CAR–TSeeking Alpha Gilead agrees to buy Kite Pharma, leaping into CAR–T cancer therapySTAT Business Insider –Motley Fool –Barron’s –Zacks Investment Research all 364 news articles » |
Stanford Medical Center Report |
Online game challenges players to design on/off switch for CRISPR
Stanford Medical Center Report A gene editor as powerful as CRISPR could have unexpected effects inside living cells, so it makes sense to turn it off when it’s not needed. In addition, an on/off switch might be able to put CRISPR-influenced genes on a sort of timer, activating and … Gamers to build on/off switches for CRISPR | Scope BlogScope (blog) |